Key result
Cardiac myosin inhibitors improve symptoms and cardiac function in oHCM, shifting the therapeutic paradigm.
Why the study?
Traditional therapies provide symptomatic relief in HCM without addressing the disease state at the cellular level, prompting the emergence of new targeted therapies.
Cardiac myosin inhibitors represent a paradigm shift in the management of obstructive hypertrophic cardiomyopathy by targeting the disease at the cellular level.
May support myosin inhibitors for obstructive HCM symptoms; leaves open need for RCTs before practice change.
Hypertrophic Cardiomyopathy (HCM) is the most commonly inherited cardiomyopathy worldwide, characterized by left ventricular hypertrophy and hypercontractility. Many cases of HCM are due to pathogenic changes in cardiac sarcomere proteins. Traditional therapies including B-blockers, non-dihydropyridine calcium channel blockers and septal reduction therapy have long provided symptomatic relief, but they have not necessarily addressed the disease state at the cellular level. The treatment landscape for HCM has evolved significantly over the last decade with the emergence of new targeted therapies, including a new class of medication called cardiac myosin inhibitors (CMI). CMI therapy represents a paradigm shift in the management of obstructive variants of HCM, offering meaningful improvement in symptoms and cardiac function parameters. CMI therapy remains investigational in the treatment of non-obstructive variants of HCM. This review examines the evolving understanding of HCM and highlights both traditional management strategies and emerging therapies.
No takes yet. Share an insight, caveat, or question.
Arroues et al. (2026) studied this question. Cardiac myosin inhibitors provide meaningful symptom and cardiac function improvements in obstructive hypertrophic cardiomyopathy, representing a therapy paradigm shift.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: